Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 32 | 2024 | 22131 | 2.110 |
Why?
|
Lung Neoplasms | 26 | 2024 | 13383 | 1.730 |
Why?
|
Minority Groups | 10 | 2024 | 1202 | 1.650 |
Why?
|
Sexual Dysfunction, Physiological | 4 | 2024 | 361 | 1.360 |
Why?
|
Medical Oncology | 16 | 2024 | 2317 | 1.350 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 17 | 2024 | 5319 | 1.200 |
Why?
|
Hematology | 3 | 2023 | 243 | 1.140 |
Why?
|
Physicians, Women | 3 | 2023 | 509 | 1.050 |
Why?
|
Immunotherapy | 8 | 2024 | 4642 | 0.890 |
Why?
|
Physicians | 6 | 2024 | 4583 | 0.870 |
Why?
|
Medical Tourism | 1 | 2023 | 52 | 0.850 |
Why?
|
Sexuality | 1 | 2024 | 180 | 0.840 |
Why?
|
Vaginal Diseases | 1 | 2023 | 103 | 0.830 |
Why?
|
Weather | 1 | 2023 | 231 | 0.790 |
Why?
|
Thoracic Neoplasms | 1 | 2024 | 267 | 0.770 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2024 | 258 | 0.760 |
Why?
|
Electronics | 1 | 2022 | 317 | 0.730 |
Why?
|
Mentors | 2 | 2023 | 661 | 0.720 |
Why?
|
Medicine | 2 | 2024 | 942 | 0.710 |
Why?
|
Emigrants and Immigrants | 2 | 2023 | 544 | 0.680 |
Why?
|
Peer Group | 1 | 2024 | 692 | 0.630 |
Why?
|
Humans | 118 | 2024 | 760740 | 0.590 |
Why?
|
Breast Neoplasms, Male | 2 | 2020 | 212 | 0.590 |
Why?
|
Early Detection of Cancer | 5 | 2024 | 3196 | 0.560 |
Why?
|
Climate Change | 1 | 2023 | 500 | 0.550 |
Why?
|
Clinical Trials as Topic | 6 | 2022 | 7995 | 0.550 |
Why?
|
Delivery of Health Care | 5 | 2023 | 5334 | 0.530 |
Why?
|
Research Personnel | 1 | 2020 | 588 | 0.510 |
Why?
|
Hedgehog Proteins | 1 | 2020 | 768 | 0.510 |
Why?
|
Faculty, Medical | 1 | 2023 | 1204 | 0.470 |
Why?
|
Social Support | 1 | 2024 | 2174 | 0.460 |
Why?
|
Healthcare Disparities | 9 | 2024 | 3351 | 0.460 |
Why?
|
Career Choice | 3 | 2023 | 757 | 0.450 |
Why?
|
Latin America | 4 | 2023 | 407 | 0.450 |
Why?
|
Registries | 3 | 2024 | 8209 | 0.440 |
Why?
|
Patient Compliance | 1 | 2023 | 2688 | 0.420 |
Why?
|
Congresses as Topic | 2 | 2023 | 802 | 0.410 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2022 | 1187 | 0.400 |
Why?
|
Female | 50 | 2024 | 392203 | 0.390 |
Why?
|
Education, Medical | 1 | 2024 | 1725 | 0.390 |
Why?
|
Papillomavirus Infections | 1 | 2023 | 1612 | 0.370 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2057 | 0.370 |
Why?
|
Women's Health | 1 | 2020 | 2066 | 0.370 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2023 | 2020 | 0.370 |
Why?
|
Names | 1 | 2020 | 54 | 0.360 |
Why?
|
Biomedical Research | 2 | 2020 | 3426 | 0.350 |
Why?
|
Curriculum | 1 | 2023 | 3739 | 0.340 |
Why?
|
Sex Characteristics | 1 | 2020 | 2637 | 0.330 |
Why?
|
Sex Factors | 7 | 2023 | 10549 | 0.330 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2020 | 1727 | 0.320 |
Why?
|
Breast Neoplasms | 7 | 2023 | 20988 | 0.320 |
Why?
|
Videoconferencing | 1 | 2021 | 203 | 0.320 |
Why?
|
Patient Selection | 3 | 2023 | 4237 | 0.310 |
Why?
|
Ventriculoperitoneal Shunt | 1 | 2019 | 187 | 0.300 |
Why?
|
Quality of Life | 2 | 2024 | 13359 | 0.300 |
Why?
|
Nerve Tissue Proteins | 1 | 2020 | 4408 | 0.290 |
Why?
|
Awards and Prizes | 1 | 2021 | 360 | 0.280 |
Why?
|
Teaching Rounds | 1 | 2021 | 276 | 0.280 |
Why?
|
South America | 2 | 2024 | 179 | 0.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 11735 | 0.270 |
Why?
|
Societies, Medical | 5 | 2023 | 3901 | 0.260 |
Why?
|
United States | 22 | 2024 | 72292 | 0.260 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 339 | 0.250 |
Why?
|
Gynecology | 1 | 2021 | 526 | 0.250 |
Why?
|
Esophageal Fistula | 1 | 2015 | 59 | 0.240 |
Why?
|
Gastroenterology | 1 | 2021 | 580 | 0.240 |
Why?
|
Bronchial Fistula | 1 | 2015 | 83 | 0.240 |
Why?
|
Health Status Disparities | 2 | 2024 | 1846 | 0.240 |
Why?
|
Cultural Diversity | 1 | 2018 | 369 | 0.240 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 26065 | 0.240 |
Why?
|
Radiation Oncology | 1 | 2020 | 563 | 0.230 |
Why?
|
Male | 32 | 2024 | 360402 | 0.230 |
Why?
|
Obstetrics | 1 | 2021 | 666 | 0.230 |
Why?
|
Acetonitriles | 1 | 2024 | 54 | 0.230 |
Why?
|
Social Environment | 1 | 2019 | 1021 | 0.230 |
Why?
|
Breast | 2 | 2020 | 1963 | 0.220 |
Why?
|
Smoking | 1 | 2020 | 9054 | 0.220 |
Why?
|
Health Services Accessibility | 6 | 2024 | 5430 | 0.220 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2022 | 4021 | 0.220 |
Why?
|
Committee Membership | 1 | 2023 | 17 | 0.220 |
Why?
|
Pandemics | 5 | 2022 | 8652 | 0.210 |
Why?
|
Educational Status | 1 | 2020 | 2509 | 0.210 |
Why?
|
Neoplasm Staging | 4 | 2024 | 11118 | 0.210 |
Why?
|
Self-Help Groups | 1 | 2024 | 192 | 0.210 |
Why?
|
Patient Participation | 1 | 2022 | 1443 | 0.210 |
Why?
|
Caribbean Region | 1 | 2023 | 192 | 0.210 |
Why?
|
Workplace | 1 | 2019 | 863 | 0.210 |
Why?
|
Pancreatic Neoplasms | 1 | 2020 | 5369 | 0.200 |
Why?
|
Radiosurgery | 1 | 2022 | 1339 | 0.200 |
Why?
|
Burnout, Professional | 1 | 2021 | 703 | 0.200 |
Why?
|
Disabled Persons | 1 | 2021 | 1226 | 0.190 |
Why?
|
Demography | 2 | 2024 | 1643 | 0.190 |
Why?
|
Aged | 18 | 2024 | 169092 | 0.190 |
Why?
|
Central Nervous System Neoplasms | 1 | 2019 | 915 | 0.180 |
Why?
|
Access to Information | 1 | 2024 | 316 | 0.180 |
Why?
|
Attitude of Health Personnel | 2 | 2022 | 3882 | 0.180 |
Why?
|
Terminal Care | 1 | 2022 | 1755 | 0.180 |
Why?
|
Practice Guidelines as Topic | 3 | 2024 | 7390 | 0.180 |
Why?
|
Comorbidity | 2 | 2021 | 10507 | 0.180 |
Why?
|
Brazil | 1 | 2024 | 1229 | 0.180 |
Why?
|
Pyridines | 2 | 2024 | 2875 | 0.180 |
Why?
|
Prostatic Neoplasms | 3 | 2023 | 11107 | 0.170 |
Why?
|
Sexual Behavior | 2 | 2023 | 2187 | 0.160 |
Why?
|
Time Factors | 1 | 2021 | 39908 | 0.160 |
Why?
|
Multiple Myeloma | 2 | 2018 | 5144 | 0.160 |
Why?
|
Public Health | 2 | 2023 | 2671 | 0.160 |
Why?
|
Communication | 2 | 2023 | 3851 | 0.160 |
Why?
|
Family | 2 | 2024 | 3193 | 0.160 |
Why?
|
Palliative Care | 2 | 2023 | 3593 | 0.150 |
Why?
|
Retrospective Studies | 11 | 2024 | 80583 | 0.150 |
Why?
|
Maximum Tolerated Dose | 1 | 2020 | 883 | 0.150 |
Why?
|
Middle Aged | 16 | 2024 | 220603 | 0.150 |
Why?
|
Exercise Therapy | 1 | 2024 | 929 | 0.150 |
Why?
|
Social Justice | 1 | 2022 | 478 | 0.150 |
Why?
|
Travel | 1 | 2023 | 796 | 0.140 |
Why?
|
Internship and Residency | 2 | 2023 | 5878 | 0.140 |
Why?
|
RNA, Neoplasm | 1 | 2020 | 749 | 0.140 |
Why?
|
Fatigue | 1 | 2024 | 1550 | 0.140 |
Why?
|
Anilides | 1 | 2020 | 411 | 0.140 |
Why?
|
Parental Leave | 2 | 2023 | 93 | 0.140 |
Why?
|
Prognosis | 5 | 2023 | 29601 | 0.140 |
Why?
|
Pyrimidines | 2 | 2024 | 3027 | 0.140 |
Why?
|
Pregnancy | 6 | 2024 | 29869 | 0.140 |
Why?
|
Drug Tolerance | 1 | 2018 | 367 | 0.140 |
Why?
|
Job Satisfaction | 2 | 2021 | 544 | 0.130 |
Why?
|
Treatment Refusal | 1 | 2019 | 429 | 0.130 |
Why?
|
Fellowships and Scholarships | 3 | 2023 | 1116 | 0.130 |
Why?
|
Melanoma | 2 | 2019 | 5696 | 0.130 |
Why?
|
Self Report | 2 | 2024 | 3727 | 0.130 |
Why?
|
Sex Distribution | 1 | 2020 | 2278 | 0.120 |
Why?
|
Heart Diseases | 1 | 2018 | 2778 | 0.120 |
Why?
|
Patient Care | 2 | 2022 | 621 | 0.120 |
Why?
|
Vascular Surgical Procedures | 1 | 2023 | 1489 | 0.120 |
Why?
|
Forecasting | 1 | 2023 | 2924 | 0.120 |
Why?
|
Cost of Illness | 1 | 2024 | 1937 | 0.120 |
Why?
|
International Cooperation | 2 | 2020 | 1422 | 0.110 |
Why?
|
Feasibility Studies | 1 | 2024 | 5239 | 0.110 |
Why?
|
Urban Population | 1 | 2022 | 2034 | 0.110 |
Why?
|
Piperazines | 1 | 2024 | 2521 | 0.110 |
Why?
|
Adult | 11 | 2024 | 220995 | 0.110 |
Why?
|
Sirolimus | 1 | 2020 | 1533 | 0.110 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.100 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3209 | 0.100 |
Why?
|
Fertility | 2 | 2024 | 769 | 0.100 |
Why?
|
Education, Medical, Graduate | 3 | 2023 | 2373 | 0.100 |
Why?
|
Hospitals | 2 | 2023 | 3879 | 0.100 |
Why?
|
Spain | 1 | 2023 | 487 | 0.100 |
Why?
|
Caregivers | 1 | 2024 | 2241 | 0.100 |
Why?
|
Lactams | 1 | 2022 | 156 | 0.100 |
Why?
|
Pilot Projects | 1 | 2024 | 8619 | 0.090 |
Why?
|
Organophosphorus Compounds | 1 | 2022 | 206 | 0.090 |
Why?
|
Rural Population | 1 | 2022 | 2277 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9277 | 0.090 |
Why?
|
Advance Directives | 1 | 2022 | 249 | 0.090 |
Why?
|
Insurance Coverage | 1 | 2022 | 1937 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6305 | 0.090 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4910 | 0.080 |
Why?
|
Venezuela | 1 | 2019 | 73 | 0.080 |
Why?
|
Lung | 2 | 2023 | 9999 | 0.080 |
Why?
|
Antineoplastic Agents | 3 | 2024 | 13635 | 0.080 |
Why?
|
Aminopyridines | 1 | 2022 | 573 | 0.080 |
Why?
|
Biopsy | 1 | 2020 | 6763 | 0.080 |
Why?
|
Etoposide | 1 | 2019 | 634 | 0.070 |
Why?
|
Exercise | 1 | 2024 | 5886 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2018 | 2218 | 0.070 |
Why?
|
Policy | 1 | 2021 | 506 | 0.070 |
Why?
|
Population Surveillance | 1 | 2018 | 2597 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 4172 | 0.070 |
Why?
|
Indians, North American | 1 | 2020 | 351 | 0.070 |
Why?
|
Prevalence | 2 | 2023 | 15702 | 0.070 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 3805 | 0.070 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 997 | 0.070 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2018 | 426 | 0.070 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7805 | 0.060 |
Why?
|
Decision Making | 1 | 2019 | 3919 | 0.060 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 583 | 0.060 |
Why?
|
Culture | 1 | 2019 | 623 | 0.060 |
Why?
|
Risk Assessment | 2 | 2021 | 23974 | 0.060 |
Why?
|
Paclitaxel | 1 | 2022 | 1730 | 0.060 |
Why?
|
Research | 2 | 2023 | 1977 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2019 | 1835 | 0.060 |
Why?
|
Philippines | 1 | 2024 | 90 | 0.060 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 15498 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2020 | 3410 | 0.060 |
Why?
|
Cuba | 1 | 2024 | 48 | 0.060 |
Why?
|
Mastectomy, Segmental | 1 | 2019 | 955 | 0.060 |
Why?
|
Central America | 1 | 2024 | 69 | 0.060 |
Why?
|
Dominican Republic | 1 | 2024 | 77 | 0.060 |
Why?
|
Education, Medical, Continuing | 1 | 2019 | 825 | 0.060 |
Why?
|
Cisplatin | 1 | 2019 | 1650 | 0.050 |
Why?
|
BRCA2 Protein | 1 | 2018 | 797 | 0.050 |
Why?
|
Interviews as Topic | 1 | 2020 | 2697 | 0.050 |
Why?
|
Hospitalization | 1 | 2023 | 10708 | 0.050 |
Why?
|
Puerto Rico | 1 | 2024 | 378 | 0.050 |
Why?
|
Pneumonectomy | 1 | 2019 | 1119 | 0.050 |
Why?
|
Pyrazoles | 1 | 2022 | 2008 | 0.050 |
Why?
|
Medically Underserved Area | 1 | 2024 | 254 | 0.050 |
Why?
|
BRCA1 Protein | 1 | 2018 | 1149 | 0.050 |
Why?
|
Leadership | 1 | 2021 | 1385 | 0.050 |
Why?
|
Mexico | 1 | 2024 | 757 | 0.050 |
Why?
|
Bronchi | 1 | 2015 | 846 | 0.050 |
Why?
|
Mastectomy | 1 | 2019 | 1817 | 0.050 |
Why?
|
Menopause | 1 | 2019 | 1645 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3514 | 0.050 |
Why?
|
Prospective Studies | 2 | 2024 | 54364 | 0.050 |
Why?
|
Censuses | 1 | 2022 | 198 | 0.050 |
Why?
|
Thalidomide | 1 | 2016 | 885 | 0.040 |
Why?
|
Oligopeptides | 1 | 2016 | 1185 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2016 | 2218 | 0.040 |
Why?
|
Adolescent | 3 | 2023 | 88247 | 0.040 |
Why?
|
Masks | 1 | 2022 | 208 | 0.040 |
Why?
|
Advisory Committees | 1 | 2024 | 787 | 0.040 |
Why?
|
Bronchoscopy | 1 | 2015 | 909 | 0.040 |
Why?
|
Risk Factors | 2 | 2023 | 74128 | 0.040 |
Why?
|
Data Collection | 1 | 2018 | 3316 | 0.040 |
Why?
|
Developing Countries | 1 | 2022 | 2868 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2022 | 422 | 0.040 |
Why?
|
Receptor, erbB-2 | 1 | 2019 | 2553 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6473 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6807 | 0.040 |
Why?
|
Mammography | 1 | 2020 | 2430 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5811 | 0.040 |
Why?
|
Dexamethasone | 1 | 2016 | 1946 | 0.040 |
Why?
|
Vulnerable Populations | 1 | 2024 | 705 | 0.040 |
Why?
|
Death | 1 | 2023 | 674 | 0.040 |
Why?
|
Intensive Care Units | 2 | 2022 | 3743 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2812 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2023 | 1333 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8516 | 0.040 |
Why?
|
Signal Transduction | 1 | 2020 | 23415 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2022 | 4010 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2023 | 58919 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10203 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2022 | 835 | 0.030 |
Why?
|
Health Facilities | 1 | 2022 | 578 | 0.030 |
Why?
|
Survival Analysis | 1 | 2019 | 10072 | 0.030 |
Why?
|
Mass Screening | 1 | 2022 | 5425 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1745 | 0.030 |
Why?
|
Logistic Models | 1 | 2020 | 13248 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 5672 | 0.030 |
Why?
|
Health Personnel | 1 | 2019 | 3333 | 0.030 |
Why?
|
Kidney Diseases | 1 | 2016 | 2090 | 0.030 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2015 | 1462 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2020 | 64572 | 0.030 |
Why?
|
Recurrence | 1 | 2016 | 8426 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 8542 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6483 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5304 | 0.030 |
Why?
|
Cause of Death | 1 | 2022 | 3683 | 0.020 |
Why?
|
Health Policy | 1 | 2023 | 2682 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2630 | 0.020 |
Why?
|
Delirium | 1 | 2001 | 1667 | 0.020 |
Why?
|
Odds Ratio | 1 | 2022 | 9644 | 0.020 |
Why?
|
Critical Care | 1 | 2001 | 2691 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20556 | 0.020 |
Why?
|
Insurance, Health | 1 | 2019 | 2495 | 0.020 |
Why?
|
Anxiety | 1 | 2001 | 4573 | 0.020 |
Why?
|
Medicare | 1 | 2023 | 6774 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2022 | 15829 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36401 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 59191 | 0.010 |
Why?
|
Depression | 1 | 2001 | 8132 | 0.010 |
Why?
|
Colombia | 1 | 2001 | 282 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39062 | 0.010 |
Why?
|
Psychotropic Drugs | 1 | 2001 | 888 | 0.010 |
Why?
|
Child | 1 | 2023 | 80089 | 0.010 |
Why?
|
Drug Utilization | 1 | 2001 | 1186 | 0.010 |
Why?
|
Cohort Studies | 1 | 2018 | 41464 | 0.010 |
Why?
|
Alcoholism | 1 | 2001 | 1972 | 0.010 |
Why?
|
Concepts
(269)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(35)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_